Michael Goldstein

Michael Goldstein joined Ocular Therapeutix in September of 2017. Prior to joining the company, Michael Goldstein served as Chief Medical Officer of Applied Genetic Technologies Corp (AGTC), a clinical-stage biotechnology company focused on the development of products for the treatment of rare diseases, with a focus in ophthalmology. Before joining AGTC, Michael Goldstein held several positions of increasing responsibility with Eleven Biotherapeutics, including Chief Medical Officer and Vice President of Clinical Research. Since 2002, Michael Goldstein has served as Co-Director, Cornea and External Disease Service and Assistant Professor of Ophthalmology at the New England Eye Center and Tufts University School of Medicine. Previously, he was Director of Refractory Surgery Service and Assistant Professor of Ophthalmology at the University of Florida College of Medicine. Michael Goldstein has published extensively and is a reviewer for multiple ophthalmology scientific journals. Michael Goldstein holds an M.D. from Northwestern University Medical School, an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management, and received his B.A. in Political Economy from Williams College.

Michael Goldstein is the Chief Strategy Advisor at Ocular Therapeutix, based in United States, North America. With a background in Biotechnology, Michael Goldstein has a rich history of leadership and innovation.Michael Goldstein studied BA Political Economy at Williams College. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.